Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.
Galot R, Le Tourneau C, Saada-Bouzid E, Daste A, Even C, Debruyne P, Henry S, Zanetta S, Rutten A, Licitra L, Canon JL, Kaminsky MC, Specenier P, Rottey S, Guigay J, Kong A, Tinhofer I, Borcoman E, Dirix L, Raveloarivahy T, Fortpied C, Vanlancker M, Morfouace M, Govaerts AS, Machiels JP. Galot R, et al. Eur J Cancer. 2021 Oct 9;158:17-26. doi: 10.1016/j.ejca.2021.09.003. Online ahead of print. Eur J Cancer. 2021. PMID: 34638090
Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S, Saada-Bouzid E, Tresch E, Ryckewaert T, Bompas E, Italiano A, Guillemet C, Peugniez C, Piperno-Neumann S, Thyss A, Maynou C, Clisant S, Penel N; French Sarcoma Group. Taieb S, et al. Eur J Cancer. 2015 Jan;51(2):202-9. doi: 10.1016/j.ejca.2014.11.008. Epub 2014 Dec 9. Eur J Cancer. 2015. PMID: 25499439
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L, Chauffert B, Blay JY, Le Cesne A, Chevreau C, Bompas E, Bertucci F, Cupissol D, Fabbro M, Saada-Bouzid E, Duffaud F, Feuvret L, Bonneville-Levard A, Bay JO, Vauleon E, Vinceneux A, Noel G, Penel N, Mir O. Lebellec L, et al. Eur J Cancer. 2017 Jul;79:119-128. doi: 10.1016/j.ejca.2017.03.037. Epub 2017 May 4. Eur J Cancer. 2017. PMID: 28478340
Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J, Sâada-Bouzid E, Peyrade F, Michel C. Guigay J, et al. Curr Treat Options Oncol. 2019 Jun 25;20(8):65. doi: 10.1007/s11864-019-0664-z. Curr Treat Options Oncol. 2019. PMID: 31240480 Review.
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C. Saleh K, et al. Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28. Eur J Cancer. 2019. PMID: 31574417
76 results